Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial
Date published:
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial
Date published:
Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE
Date published:
CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL
Date published:
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS
Date published:
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Date published:
EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM
Date published:
Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE
Date published:
GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)
Date published:
VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE
Date published:
THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL
Date published:
THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL
Date published:
THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO ALBUMINURIA AT BASELINE: RESULTS FROM PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL
Date published:
THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE SERUM URATE LEVEL: RESULTS FROM POST HOC ANALYSES OF THE CKD-FIX TRIAL
Date published:
THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO DIABETIC KIDNEY DISEASE AT BASELINE: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL
Date published:
Effects of canagliflozin on cardiovascular death and hospitalisation for heart failure by eGFR: integrated analyses of the CANVAS Program and CREDENCE
